Kiromic Biopharma (KRBP)
OTHER OTC:KRBP
US Market
Holding KRBP?
Track your performance easily

Kiromic Biopharma (KRBP) Income Statement

19 Followers

Kiromic Biopharma Income Statement

Last quarter (Q ), Kiromic Biopharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Kiromic Biopharma's net income was $-7.43M. See Kiromic Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
-----$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 22.36M$ 19.94M$ 31.11M$ 25.74M$ 19.20M$ 3.71M
Operating Income
$ -22.36M$ -19.94M$ -31.11M$ -25.74M$ -19.20M$ -3.71M
Net Non Operating Interest Income Expense
$ -3.30M$ 1.85M$ 166.50K$ -12.20K$ -3.30K$ -22.50K
Other Income Expense
$ 1.15M$ 842.20K$ -3.45M$ -159.20K$ -1.04M-
Pretax Income
$ -27.17M$ -20.95M$ -34.73M$ -25.59M$ -19.20M$ -3.73M
Tax Provision
-----$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -27.17M$ -23.50M$ -35.08M$ -25.81M$ -19.91M$ -3.98M
Basic EPS
$ -278.43$ -12.59$ -64.42$ -67.80$ -132.60$ -1.06
Diluted EPS
$ -278.43$ -12.59$ -64.42$ -67.80$ -132.60$ -1.06
Basic Average Shares
$ 5.46M$ 1.10M$ 544.48K$ 380.57K$ 150.19K$ 3.53M
Diluted Average Shares
$ 5.46M$ 1.10M$ 544.48K$ 380.57K-$ 3.53M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 22.36M$ 19.94M$ 31.11M$ 25.74M$ 19.20M$ 3.71M
Net Income From Continuing And Discontinued Operation
$ -27.17M$ -20.95M$ -34.73M$ -25.59M$ -19.20M$ -3.73M
Normalized Income
$ -7.36M----$ -3.73M
Interest Expense
-----$ 22.50K
EBIT
$ -23.87M$ -19.10M$ -34.56M$ -25.58M$ -19.20M$ -3.71M
EBITDA
$ -20.55M$ -16.88M$ -32.89M$ -25.11M$ -19.00M$ -3.71M
Currency in USD

Kiromic Biopharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis